MTOR and tuberous sclerosis: Previous studies demonstrated that dual inhibition of the mTOR and MAPK signaling pathways effectively blocked Tsc−/− cell proliferation in vitro, and provided a proof-of-concept demonstration that combination therapy targeting both mTOR and MAPK signaling pathways may have the potential to become a novel strategy for the treatment of TSC patients [26,27].